982 related articles for article (PubMed ID: 26720853)
21. Medicare part D and changes in prescription drug use and cost burden: national estimates for the Medicare population, 2000 to 2007.
Briesacher BA; Zhao Y; Madden JM; Zhang F; Adams AS; Tjia J; Ross-Degnan D; Gurwitz JH; Soumerai SB
Med Care; 2011 Sep; 49(9):834-41. PubMed ID: 21544002
[TBL] [Abstract][Full Text] [Related]
22. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017.
Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS
J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594
[TBL] [Abstract][Full Text] [Related]
23. Cost minimization of medicare part D prescription drug plan expenditures.
Patel RA; Lipton HL; Cutler TW; Smith AR; Tsunoda SM; Stebbins MR
Am J Manag Care; 2009 Aug; 15(8):545-53. PubMed ID: 19670958
[TBL] [Abstract][Full Text] [Related]
24. Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2015 Oct; 21(10):956-64. PubMed ID: 26402394
[TBL] [Abstract][Full Text] [Related]
25. Medicare's Variation in Out-of-Pocket Costs for Prescriptions: The Irrational Examples of In-Hospital Observation and Home Infusion.
Wright B; Dusetzina SB; Upchurch G
J Am Geriatr Soc; 2018 Dec; 66(12):2249-2253. PubMed ID: 30264858
[TBL] [Abstract][Full Text] [Related]
26. Growing differences between Medicare beneficiaries with and without drug coverage.
Poisal JA; Murray L
Health Aff (Millwood); 2001; 20(2):74-85. PubMed ID: 11260961
[TBL] [Abstract][Full Text] [Related]
27. The impact of Medicare prescription drug coverage on the use of antidementia drugs.
Fowler NR; Chen YF; Thurton CA; Men A; Rodriguez EG; Donohue JM
BMC Geriatr; 2013 Apr; 13():37. PubMed ID: 23621892
[TBL] [Abstract][Full Text] [Related]
28. Prescription Drug Spending in Fee-for-Service Medicare, 2008-2019.
Dusetzina SB; Huskamp HA; Qin X; Keating NL
JAMA; 2022 Oct; 328(15):1515-1522. PubMed ID: 36255428
[TBL] [Abstract][Full Text] [Related]
29. The impact of Medicare part D on income-related inequality in pharmaceutical expenditure.
Carvalho N; Petrie D; Chen L; Salomon JA; Clarke P
Int J Equity Health; 2019 Apr; 18(1):57. PubMed ID: 30992000
[TBL] [Abstract][Full Text] [Related]
30. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
Patel UD; Davis MM
J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
[TBL] [Abstract][Full Text] [Related]
31. Five-year impact of Medicare Part D coverage gap reform on drug expenditures and utilization.
Park J; Look KA
Health Serv Res; 2022 Feb; 57(1):56-65. PubMed ID: 33870486
[TBL] [Abstract][Full Text] [Related]
32. Effect of Medicare Part D and insurance type on Medicare beneficiary access to prescription medication and use of prescription cost-saving measures.
Urmie JM; Farris KB; Doucette WR; Goedken AM
J Am Pharm Assoc (2003); 2011; 51(1):72-81. PubMed ID: 21247829
[TBL] [Abstract][Full Text] [Related]
33. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
34. Associations Between Annual Medicare Part D Low-Income Subsidy Loss and Prescription Drug Spending and Use.
Fung V; Price M; Cheng D; Patel TA; Yang Z; Hsu J; Alegria M; Newhouse JP
JAMA Health Forum; 2024 Feb; 5(2):e235152. PubMed ID: 38306091
[TBL] [Abstract][Full Text] [Related]
35. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
36. Outpatient prescription drug utilization and expenditure patterns of noninstitutionalized aged Medicare beneficiaries.
LaVange LM; Silverman HA
Natl Med Care Util Expend Surv B; 1987 Apr; (12):1-43. PubMed ID: 10313516
[TBL] [Abstract][Full Text] [Related]
37. Out-of-plan medication in Medicare Part D.
Roberto PN; Stuart B
Am J Manag Care; 2014 Sep; 20(9):743-8. PubMed ID: 25365749
[TBL] [Abstract][Full Text] [Related]
38. The effect of Medicare Part D on drug and medical spending.
Zhang Y; Donohue JM; Lave JR; O'Donnell G; Newhouse JP
N Engl J Med; 2009 Jul; 361(1):52-61. PubMed ID: 19571283
[TBL] [Abstract][Full Text] [Related]
39. An overview and study of beneficiaries' knowledge, attitudes, and perceptions of the medicare part d benefit.
Woelfel JA; Patel RA; Lee H; Chu S; Ranson C; Patel B; Italia U; Walberg MP; Carr-Lopez SM; Galal SM
Consult Pharm; 2015 Feb; 30(2):101-11. PubMed ID: 25695416
[TBL] [Abstract][Full Text] [Related]
40. Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia.
Li P; McElligott S; Bergquist H; Schwartz JS; Doshi JA
Ann Intern Med; 2012 Jun; 156(11):776-84, W-263, W-264, W-265, W-266, W-267, W-268, W-269. PubMed ID: 22665815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
